HighTower Advisors’s Protagonist Therapeutics PTGX Stock Holding History

HighTower Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$651K	Sell	5,308 -78	-1%	-$8.15K	﹤0.01%	2542
2026 Q1	$568K	Sell	5,386 -1,741	-24%	-$154K	﹤0.01%	2608
2025 Q4	$622K	Sell	7,127 -1,486	-17%	-$122K	﹤0.01%	2454
2025 Q3	$572K	Sell	8,613 -1,367	-14%	-$77.7K	﹤0.01%	2508
2025 Q2	$552K	Buy	9,980 +3,462	+53%	+$166K	﹤0.01%	2437
2025 Q1	$315K	Buy	+6,518	New	+$273K	﹤0.01%	2820
2024 Q4	–	Sell	-10,887	Closed	-$487K	–	4010
2024 Q3	$487K	Sell	10,887 -12,897	-54%	-$521K	﹤0.01%	2411
2024 Q2	$828K	Buy	+23,784	New	+$697K	﹤0.01%	1959

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

HighTower Advisors's PTGX Position: Q2 2026 in Review

HighTower Advisors reduced its Protagonist Therapeutics (PTGX) stake by 1.4% in Q2 2026, selling an estimated $8.15K and leaving 5,308 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #2542.

HighTower Advisors first reported a position in PTGX in Q2 2024 and has held it in 8 quarters since. The position peaked at $828K in Q2 2024. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

HighTower Advisors held 5,308 shares of Protagonist Therapeutics worth $651K as of Q2 2026.
HighTower Advisors sold 78 Protagonist Therapeutics shares in Q2 2026, an estimated $8.15K.
Protagonist Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2542 holding.
HighTower Advisors first reported a position in Protagonist Therapeutics in Q2 2024 and has held it in 8 quarters since.
HighTower Advisors's Protagonist Therapeutics position peaked at $828K in Q2 2024.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.